Multiple Sclerosis (MS)

Select from the various topics below and click on the link to get an inside view of how our P&T committee responded to the issue. 

PML Cases with Monotherapy Tysabri Worldwide Since Reintroduction to the Market

Comparative Efficacy of Interferons and Copaxone vs. Higher Side Effects for Tysabri

Novartis and Bayer Agreement on Extavia as a Market Entry Strategy

Copaxone, Betaseron, Avonex and Rebif Clinical Differentiation

Earlier Use of Interferons and Copaxone in Disease Progression

Importance of New Indications Highlighting Copaxone's New Indication for First Clinical Episode

Impact of Injection Site Reactions with Rebif as Compared to Avonex on Compliance and Preference

Impact on Compliance and Preference of IM Injection with Avonex as Compared to Subcutaneous Injection with Rebif and Betaseron

Financial and Contracting Comparison of Rebif and Betaseron

Efficacy and Side Effect Comparison of Rebif, Betaseron and Avonex

Effect of Neutralizing Antibodies on Response Rate for Interferons and Copaxone

Neurologist Preference Among Avonex, Betaseron adn Rebif: Higher Potency vs. More Frequent Dosing

Neurologist Therapy Protocol for First-line Biologics

Cost Comparison Across Avonex, Rebif, Betaseron and Copaxone

Total Cost and Utilization Associated with Members with MS

Formulary Essentials Among Copaxone, Avonex, Rebif and Betaseron

Contracting Changes Moving Non-preferred Agents to Preferred and Moving Share Consideration

PA Requirements for Avonex and Betaseron

Betaseron and Extavia Comparison

Extavia Price Threshold to Obtain Preferred Status

Patient Willingness to Switch for Lower OOP Costs


* PTP video clips play in windows media player.  To download click here, Mac users click here
 

top of page